BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22549696)

  • 1. Bleeding and thrombosis in acute promyelocytic leukemia.
    Choudhry A; DeLoughery TG
    Am J Hematol; 2012 Jun; 87(6):596-603. PubMed ID: 22549696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
    Escudier SM; Kantarjian HM; Estey EH
    Leuk Lymphoma; 1996 Feb; 20(5-6):435-9. PubMed ID: 8833399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
    Korístek Z; Zák P
    Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.
    Pogliani EM; Rossini F; Casaroli I; Maffe P; Corneo G
    Acta Haematol; 1997; 97(4):228-30. PubMed ID: 9158667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage.
    Hashimoto S; Koike T; Tatewaki W; Seki Y; Sato N; Azegami T; Tsukada N; Takahashi H; Kimura H; Ueno M
    Leukemia; 1994 Jul; 8(7):1113-5. PubMed ID: 8035603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Therapeutically Related Drugs on Coagulation-Anticoagulation Balance in Acute Promyelocytic Leukemia.
    Xiao M; Zhou P; Sun K
    Clin Appl Thromb Hemost; 2022; 28():10760296221080166. PubMed ID: 35187963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia.
    Tallman MS; Abutalib SA; Altman JK
    Semin Thromb Hemost; 2007 Jun; 33(4):330-8. PubMed ID: 17525890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.
    Kwaan HC; Cull EH
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):11-8. PubMed ID: 24907013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombosis during all-trans-retinoic acid therapy in a child with acute promyelocytic leukemia and factor VQ 506 mutation.
    Koçak U; Gürsel T; Oztürk G; Kantarci S
    Pediatr Hematol Oncol; 2000 Mar; 17(2):177-80. PubMed ID: 10734661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiplasmin drugs and factor XIII concentrates in the treatment of a patient with acute promyelocytic leukemia (M3)].
    Ryo R; Sugano W; Yoshida A; Adachi M; Yasunaga M; Yoneda N; Saigo K; Kondo S; Yamaguchi N; Nobusawa A
    Gan No Rinsho; 1989 Oct; 35(12):1479-82. PubMed ID: 2810783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
    Komatsu N
    Int J Hematol; 2014 Jul; 100(1):16-7. PubMed ID: 24912657
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute promyelocytic leukemia: where did we start, where are we now, and the future.
    Coombs CC; Tavakkoli M; Tallman MS
    Blood Cancer J; 2015 Apr; 5(4):e304. PubMed ID: 25885425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients.
    Dally N; Hoffman R; Haddad N; Sarig G; Rowe JM; Brenner B
    Thromb Res; 2005; 116(2):109-14. PubMed ID: 15907524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom.
    Tallman MS; Brenner B; Serna Jde L; Dombret H; Falanga A; Kwaan HC; Liebman H; Raffoux E; Rickles FR
    Leuk Res; 2005 Mar; 29(3):347-51. PubMed ID: 15661272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with all-trans-retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage.
    Dombret H; Sutton L; Duarte M; Daniel MT; Leblond V; Castaigne S; Degos L
    Leukemia; 1992 Dec; 6(12):1237-42. PubMed ID: 1453767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia.
    Ventura GJ; Hester JP; Dixon DO; Khorana S; Keating MJ
    Hematol Pathol; 1989; 3(1):23-8. PubMed ID: 2745357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open issues on bleeding and thrombosis in acute promyelocytic leukemia.
    Sanz MA; Montesinos P
    Thromb Res; 2010 Apr; 125 Suppl 2():S51-4. PubMed ID: 20434005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.
    Di Bona E; Avvisati G; Castaman G; Luce Vegna M; De Sanctis V; Rodeghiero F; Mandelli F
    Br J Haematol; 2000 Mar; 108(4):689-95. PubMed ID: 10792270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia.
    Higuchi T; Shimizu T; Mori H; Niikura H; Omine M
    Hematol Oncol; 1997 Nov; 15(4):209-17. PubMed ID: 9722892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.